Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 353,427 shares, a decrease of 68.5% from the February 26th total of 1,121,342 shares. Based on an average daily trading volume, of 2,134 shares, the short-interest ratio is currently 165.6 days. Based on an average daily trading volume, of 2,134 shares, the short-interest ratio is currently 165.6 days.

Innovent Biologics Stock Performance

Shares of OTCMKTS:IVBXF remained flat at $9.75 during trading on Wednesday. The stock had a trading volume of 4,400 shares, compared to its average volume of 1,963. Innovent Biologics has a one year low of $5.00 and a one year high of $15.12. The company has a fifty day moving average price of $10.68 and a two-hundred day moving average price of $11.22.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).